Please login to the form below

Not currently logged in
Email:
Password:

Abbott sues J&J over Simponi

Abbott laboratories has sued Johnson & Johnson over its drug Simponi, stating that preparations to market the drug infringe a patent issued for Humira

Abbott laboratories has sued Johnson & Johnson over its drug Simponi, stating that preparations to market the drug infringe a patent issued for Humira.

Abbott's Humira (adalimumab), which treats rheumatoid arthritis, was issued a patent in 2007. Johnson & Johnson's Centocor unit plans to introduce golimumab, a new and competing drug for the crippling disease under the brand name Simponi.

Abbott is seeking cash compensation and an order to prevent further use of its invention by Johnson & Johnson.

Scott Stoffell, Abbott's spokesperson explained: "We're not asking the court to prevent the launch of Simponi. Abbott has no plans to file for a preliminary injunction or a temporary restraining order."

In response, Brian Kenney of Johnson & Johnson's Centocor unit said: "We are currently reviewing the complaint and will vigorously contest it… We believe we have rights to all of the intellectual property we need to market Simponi."

Johnson & Johnson received approval from the Food and Drug Administration (FDA) to market the anti-TNF-alpha therapy for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis in April 2009. The drug, to be co-marketed outside the US by Schering-Plough, will compete with Humira and Amgen's Enbrel.

5th May 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics